After Moderna (MRNA) shook out the sellers in recent sessions, shares rose again on Tuesday. It added 14.36% to close at $158.83.
Investors are removing the COVID-era vaccine discount and assigning an mRNA cancer therapy premium. Together with Merck, the jointly developed therapy met its primary endpoint for a Phase 3 trial treating melanoma.
Short-sellers hold 12.5% short interest in MRNA stock.
Cisco Systems (CSCO) secured a partnership with Super Micro Computer (SMCI). The expanded Secure AI factory facilitates AI deployment.
Watch Robinhood (HOOD) today. After gaining 8.2% on Tuesday, shares might renew their rally that started late last week. Futu Holdings (FUTU) and Schwab (SCHW) are also attractive holdings.
Lithium Miner Albemarle (ALB) pulled back by 5.89%. It fell the most on the S&P 500 (IVV) when JPMorgan Chase (JPM) lowered its EBITDA forecast. It also cut the price target from $160 to $140. The bank thinks that the FY EBITDA will be $2.88 billion, down from a previous forecast of $3.37 billion.
Zscaler (ZS) fell by 4.34% to close below $170. The firm is renewing its focus on new territories to drive sales. Higher marketing efforts, along with spending resources to support existing customers, should give Zscaler’s revenue a strong boost this year.
Related Stories
